{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:26:18Z","timestamp":1780046778194,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K09702"],"award-info":[{"award-number":["JP21K09702"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10384-025-01264-6","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:33:35Z","timestamp":1755840815000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Switching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"70","author":[{"given":"Yusuke","family":"Maehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7935-4244","authenticated-orcid":false,"given":"Shoji","family":"Notomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Shiose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Hisatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"1264_CR1","doi-asserted-by":"publisher","first-page":"e106\u201316","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106-16.","journal-title":"Lancet Glob Health"},{"key":"1264_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1264_CR3","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023;12:5145.","journal-title":"J Clin Med"},{"key":"1264_CR4","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00417-024-06582-y","volume":"262","author":"Y Fukuda","year":"2024","unstructured":"Fukuda Y, Notomi S, Shiose S, Maehara Y, Kiyohara K, Fujiwara K, et al. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population. Graefes Arch Clin Exp Ophthalmol. 2024;262:3971\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1264_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:83\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"1264_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12886-024-03663-8","volume":"24","author":"R Mukai","year":"2024","unstructured":"Mukai R, Honjo J, Tanaka K, Sekiryu T. Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment. BMC Ophthalmol. 2024;24:393.","journal-title":"BMC Ophthalmol"},{"key":"1264_CR7","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747.","journal-title":"Sci Rep"},{"key":"1264_CR8","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14:11681.","journal-title":"Sci Rep"},{"key":"1264_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1264_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123:51\u20139.","journal-title":"Ophthalmology"},{"key":"1264_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/IAE.0000000000000813","volume":"36","author":"S de Massougnes","year":"2016","unstructured":"de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. Retina. 2016;36:881\u20138.","journal-title":"Retina"},{"key":"1264_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00417-020-04730-8","volume":"258","author":"LM Marquis","year":"2020","unstructured":"Marquis LM, Mantel I. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258:1591\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1264_CR13","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138.","journal-title":"Clin Ophthalmol"},{"key":"1264_CR14","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13:21128.","journal-title":"Sci Rep"},{"key":"1264_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1264_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","volume":"67","author":"T Hikichi","year":"2023","unstructured":"Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"1264_CR17","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s40123-024-01005-x","volume":"13","author":"D Veritti","year":"2024","unstructured":"Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P. Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes. Ophthalmol Ther. 2024;13:2813\u201324.","journal-title":"Ophthalmol Ther"},{"key":"1264_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8:360\u20136.","journal-title":"Ophthalmol Retina"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10384-024-01115-w","volume":"68","author":"AF Sajiki","year":"2024","unstructured":"Sajiki AF, Kataoka K, Takeuchi J, Ota H, Nakano Y, Horiguchi E, et al. Clinical utility of swept-source optical coherence tomography angiography for the diagnosis of exudative maculopathy. Jpn J Ophthalmol. 2024;68:614\u201320.","journal-title":"Jpn J Ophthalmol"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559\u201369.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1264_CR21","first-page":"476","volume":"14","author":"A Machida","year":"2024","unstructured":"Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E, et al. Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept. Life (Basel). 2024;14(4):476.","journal-title":"Life (Basel)"},{"key":"1264_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.65.11.15","volume":"65","author":"T Todoroki","year":"2024","unstructured":"Todoroki T, Takeuchi J, Ota H, Nakano Y, Sajiki AF, Nakamura K, et al. Aqueous humor cytokine analysis in age-related macular degeneration after switching from aflibercept to faricimab. Invest Ophthalmol Vis Sci. 2024;65:15.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1264_CR23","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1038\/s41598-024-59894-8","volume":"14","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, et al. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci Rep. 2024;14:9087.","journal-title":"Sci Rep"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822\u201332.","journal-title":"Ophthalmology"},{"key":"1264_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.survophthal.2023.02.004","volume":"68","author":"M Rispoli","year":"2023","unstructured":"Rispoli M, Cennamo G, Antonio LD, Lupidi M, Parravano M, Pellegrini M, et al. Practical guidance for imaging biomarkers in exudative age-related macular degeneration. Surv Ophthalmol. 2023;68:615\u201327.","journal-title":"Surv Ophthalmol"},{"key":"1264_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/aos.13364","volume":"95","author":"F Sulzbacher","year":"2017","unstructured":"Sulzbacher F, Pollreisz A, Kaider A, Kickinger S, Sacu S, Schmidt-Erfurth U. Identification and clinical role of choroidal neovascularization characteristics based on optical coherence tomography angiography. Acta Ophthalmol. 2017;95:414\u201320.","journal-title":"Acta Ophthalmol"},{"key":"1264_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00347-020-01297-x","volume":"118","author":"T Barth","year":"2021","unstructured":"Barth T, Reiners M, Zeman F, Greslechner R, Helbig H, Gamulescu MA. Anti-VEGF-therapy of fibrovascular and serous-vascularized pigment epithelial detachment in neovascular AMD: a retrospective five-year-analysis. Ophthalmologe. 2021;118:1255\u201363.","journal-title":"Ophthalmologe"},{"key":"1264_CR28","doi-asserted-by":"publisher","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","volume":"17","author":"J Canonica","year":"2023","unstructured":"Canonica J, Foxton R, Garrido MG, Lin CM, Uhles S, Shanmugam S, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion. Front Cell Neurosci. 2023;17:1192464.","journal-title":"Front Cell Neurosci"},{"key":"1264_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcp.10442","volume":"199","author":"Y Oshima","year":"2004","unstructured":"Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004;199:412\u20137.","journal-title":"J Cell Physiol"},{"key":"1264_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cyto.2007.09.001","volume":"40","author":"S Peters","year":"2007","unstructured":"Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J, et al. Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability. Cytokine. 2007;40:144\u201350.","journal-title":"Cytokine"},{"key":"1264_CR31","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857\u201367.","journal-title":"Drug Des Devel Ther"},{"key":"1264_CR32","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00417-023-06146-6","volume":"261","author":"K Lee","year":"2023","unstructured":"Lee K, Lee S, Jung S, Chin HS. Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies. Graefes Arch Clin Exp Ophthalmol. 2023;261:3581\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1264_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01264-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01264-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01264-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:36:07Z","timestamp":1772166967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01264-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01264-6","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Maehara, None; S. Notomi, None; S. Shiose, None; Y. Fukuda, None; K. Kiyohara, None; K. Kano, None; K. Ishikawa, None; T. Hisatomi, None; K. Sonoda, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}